Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abvc Biopharma Inc (NQ: ABVC )

0.7100 -0.0200 (-2.74%)
Streaming Delayed Price Updated: 2:09 PM EST, Dec 7, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 36,209
Open 0.7300
Bid (Size) 0.6500 (2)
Ask (Size) 0.7400 (1)
Prev. Close 0.7300
Today's Range 0.6700 - 0.7500
52wk Range 0.5000 - 4.260
Shares Outstanding 24,470,526
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
ABVC BioPharma Provides Vitargus Update - Phase II Vitargus Study Protocol Received Thai FDA Approval
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For November 16, 2022
Upgrades 
Via Benzinga

Performance

YTD
-78.81%
-78.81%
1 Month
-5.35%
-5.35%
3 Month
-34.26%
-34.26%
6 Month
-62.83%
-62.83%
1 Year
-77.53%
-77.53%

More News

Read More
ABVC BioPharma Reports Third Quarter 2022 Financial and Operational Results
Via NewMediaWire
ABVC BioPharma Receives Notice of Allowance from US Patent and Trademark Office for ABV-1504 Used to Treat Major Depressive Disorder (MDD)
Via NewMediaWire
Topics Intellectual Property
Exposures Intellectual Property
Cedars-Sinai Medical Center Joins Phase I Clinical Study of ABVC BioPharma's Medication for Treating Depression in Cancer Patients
Via NewMediaWire
ABVC BioPharma Announces Vitargus Phase II Study Plan Approved by HREC in Australia
Via NewMediaWire
Why NanoVibronix Shares Surged Over 25%; Here Are 82 Biggest Movers From Friday
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
ABVC BioPharma Provides ADHD Phase II Part 2 Clinical Study Update and Announces UCSF Institutional Review Board Approval
Via NewMediaWire
ABVC Biopharma Announces Letter to Shareholders
Via NewMediaWire
ABVC BioPharma Selects Additional Vitargus Phase II Study Site
Via NewMediaWire
Why Nikola Dropped Over 9%; Here Are 66 Biggest Movers From Yesterday
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
ABVC Provides Oncology Pipeline Updates
Via NewMediaWire
ABVC BioPharma Provides Vitargus Update
Via NewMediaWire
Exposures Product Safety
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
ABVC BioPharma Reports Second Quarter 2022 Financial and Operational Results
Via NewMediaWire
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
ABVC BioPharma Provides Vitargus Update
Via NewMediaWire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
ABVC Notes New Report That Estimates Global Retinal Surgical Instruments Market to Grow to $2.46 Billion by 2028
Via NewMediaWire
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.